Advanced search
Publication Cover
Cancer Investigation Volume 30, 2012 - Issue 2
Submit an article Journal homepage
115
Views
6
CrossRef citations to date
0
Altmetric
IMAGING, DIAGNOSIS, PROGNOSIS

Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

James R. HockerDepartments of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,
,
Erin A. BishopDepartments of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,
,
Stan A. LightfootDepartments of Pathology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,
,
Megan R. LernerDepartments of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
,
Marvin D. PeytonDepartments of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
,
Daniel J. BrackettDepartments of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
,
Rushie J. HanasDepartments of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,
,
D. Scott McMeekinDepartments of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,
,
Joan L. WalkerDepartments of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,
&
Jay S. HanasCorrespondence[email protected]
 show all
Pages 189-197 | Published online: 02 Feb 2012
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Sera mass spectrometry (MS) peak differences were analyzed from 35 ovarian cancer patients and 16 disease-free individuals. “Leave one out” cross validation was used to assign “% cancer peaks” in control and ovarian cancer sera samples. Sera MS discriminated stage I/II and stage III/V ovarian cancer patients versus controls with ROC curve area values of 0.82 and 0.92. Test sensitivities for ovarian cancer stage I/II and III/V were 80% and 93% respectively. These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.